Abbott reports in-line third-quarter results, affirms guidance; shares slip

Published 15/10/2025, 12:44
© Reuters.

Investing.com -- Abbott Laboratories shares slid over 2% in premarket trading Wednesday after the medical devices maker reported in-line third-quarter earnings and sales just shy of the consensus forecast.

The company posted earnings per share (EPS) of $1.30, matching estimates. Revenue came in at $11.37 billion, slightly below the $11.4 billion consensus forecast.

Sales rose 6.9% on a reported basis and 5.5% organically, with growth improving to 7.5% when excluding COVID-19 testing-related revenue.

"Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance," said Robert Ford, chairman and CEO of Abbott. "Our differentiated product pipeline continues to power our performance and positions Abbott to deliver durable long-term value to our shareholders."

For the full year 2025, Abbott guided for earnings of $5.12 to $5.18 per share, compared with the current consensus estimate of $5.14.

The company maintained its outlook for organic sales growth of 7.5% to 8.0% excluding COVID-19 testing impacts, or 6.0% to 7.0% when those testing revenues are included.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.